Logos Global Management LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Logos Global Management LP
CRD #305162
SEC #801-117248
CIK #0001792126
AUM 2,252.5 M (2026-04-22)
Employees 9 (56% Investors, 0% Brokers)
Fees
Minimum
Phone415-801-4660
Address1 Letterman Drive
San Francisco, CA 94129
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
3.02.41.81.20.60.02010201520212027
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
Item 5: Fees and Compensation

Investors should consult the Offering Documents for more details regarding the calculation of fees
and expenses.

Fees and Allocations
The Investors and the Funds are qualified purchasers. Therefore, information on how Logos is
compensated for its advisory services and its fee schedule are not included here. Logos’ compensation
is negotiable and varies, but is set forth generally in each Fund’s Offering Document.

The General Partners serve as the general partners of each Fund that is a limited partnership. As such,
the General Partners deduct management fees and performance allocations directly from the
applicable Funds or are distributed carried interest distributions, as applicable. Investors in a feeder
fund pay fees and allocations indirectly, through their indirect investments in the Master Fund.

Management fees are deducted in advance on the first day of each fiscal quarter, performance
allocations are allocated at the end of each fiscal year or at the time of an investor’s withdrawal or
redemption and carried interest distributions are generally made on distributions from the applicable
Funds following the return of capital to Investors. If a Fund terminates or an Investor withdraws or
redeems, the Investor (through the Master Fund) bears expenses, management fees and performance
allocations through the date of termination or withdrawal/redemption, except that if an Investor
withdraws or redeems from a Fund on a date other than the last day of a measurement period, there
is no refund to that Investor of any management fee that it previously paid for that period. Investors
may not withdraw from the Opportunities Funds or any special purpose vehicles.

Logos and its personnel may receive additional compensation in connection with management and
other services performed for portfolio companies of the Funds and such additional compensation
offsets, in part, the management fees otherwise payable to Logos to the extent provided in the
Offering Documents.

Logos provides certain Investors special management fee, performance allocation and carried interest
arrangements that it does not provide to other Investors. Logos may waive all or any portion of the
management fees, performance allocations and carried interest distributions with respect to any
Investor.

The Offering Documents of certain Opportunities Funds or special purpose vehicles permit Logos
to waive or agree to reduce its management fee, which reductions operate to reduce the amount of
capital Logos, the applicable General Partner or certain affiliated persons would otherwise be required
to contribute to that Opportunities Fund. As described in the Offering Documents, the Limited
Partners of such an Opportunities Fund are, in such circumstances, required to make special
contributions according to their respective share of the management fee to fund any contribution
corresponding to the waived or reduced management fee. As a result, the exercise of such waiver may
result in an acceleration (or delay) of investor capital contributions and depending on the timing of
waivers and contributions, it is possible that management fee reductions or waivers will not be fully
realized by investors in an Opportunities Fund, resulting in a benefit to Logos.

Performance allocations and carried interest distributions may create an incentive for Logos to make
more risky and speculative investments than it would otherwise make.

Logos believes that its fees are competitive with fees charged by other investment advisers for
comparable services. Comparable services may be available, however, from other sources for lower
fees.

Expenses
In addition to the compensation described above, each Fund bears the costs and expenses of its
formation and operation as more fully disclosed in the Offering Documents. Investors should review
the applicable Fund’s Offering Documents for a more detailed description of that Fund’s expenses.
These expenses include, but are not limited to the following: (1) trading and investment expenses,
including, as applicable, research fees and expenses; (2) legal and compliance expenses; (3) fees and
expenses related to various filings (or portions thereof) made in connection with managing the Funds’
portfolios (including, but not limited to, Section 13 filings, Form PF preparation and filings and similar
expenses (if applicable)); (4) administrator, audit (including custody audit, if applicable), tax and Fund-
related accounting expenses (including third party accounting services); (5) shareholder proxy voting
services; (6) organizational expenses; (7) interest on margin accounts and other indebtedness; (8)
borrowing charges on securities sold short; (9) custodial and bank service fees; (10) third party
valuation services; (11) expenses and costs of expert networks and costs of obtaining surveys; (12)
software, data sets and analysis or other information related to investments or sectors in which the
Funds may invest; (13) Fund-related insurance costs; (14) litigation or investigation expenses involving
Fund activities; and (15) any other expenses related to the purchase, sale or transmittal of the Funds’
assets.

Transaction-Based Compensation
From time to time and in connection with the Funds’ portfolio investments, Logos, its affiliates or its
supervised persons may receive transaction, commitment, breakup, advisory, syndication, guarantee,
directors, officers, management and other fees. Such fees received by Logos are generally offset in
whole or part against management or other fees payable to Logos by the relevant Fund(s). However,
in certain instances Logos, its affiliates or supervised persons will retain a portion of such fees without
a corresponding fee offset. Please refer to the governing documents of the applicable Fund for
complete information on additional compensation received by Logos in connection with services
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
Item 7: Types of Clients

Logos provides investment advisory services to the Funds. Investors in the Funds will include but
will not be limited to high-net-worth individuals, trusts, estates, charitable organizations, endowments,
foundations, insurance companies, funds of funds, family offices, public and corporate pension plans
and other corporate and business entities.
Investors in the Public Funds are required to make an initial minimum subscription of $5 million,
subject to waiver by Logos.
Sector Form 13F Holdings Value ($B)
Revolution Medicines Inc 0.2
Erasca Inc 0.2
IDEAYA Biosciences Inc 0.1
Praxis Precision Medicines Inc 0.1
Abivax Sa 0.1
BCTG Acquisition Corp 0.1
Cytokinetics Inc 0.1
Olema Pharmaceuticals Inc 0.0
United Therapeutics Corp 0.0
Immunocore Holdings PLC 0.0
View All
Holdings by Sector ($B)
3.02.41.81.20.60.02019202120242027
Type Form D Funds Date Sold AUM
VC Logos Opportunities Fund V LP [2026-03-31] 250.2 M
Filed 2025-02-03 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
VC Logos Opportunities Fund IV LP [2024-03-29] 284.0 M 361.9 M
Filed 2024-07-19 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
VC Logos Opportunities Fund III LP [2022-03-31] 208.1 M 68.0 M
Filed 2021-05-10 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
VC Logos SPV 1 LP [2022-03-31]
Filed 2021-01-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
VC Logos Opportunities Fund II LP [2021-03-31] 44.0 M 42.1 M
Filed 2020-02-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
VC Logos Opportunities Fund I LP [2019-12-23] 44.0 M
Filed 2020-02-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Logos Global Master Fund LP [2019-07-26] 266.1 M 1,530.3 M
Filed 2025-08-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 8 2.3
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 8 2.3
By Discretionary
Discretionary 8 2.3
Non-Discretionary 0 0.0
Total 8 2.3
By Non-United States Persons
Non-United States Persons 0.8
United States Persons 1.5
Total 8 2.3
Form D Directors Role # Filings # Firms 2011 - 2026
Ronan Guilfoyle Director 358 108
Wade Kenny Director 86 31
Virginia Yee Executive Officer 7 3
Arsani William Director, Executive Officer 9 2
Graham Walmsley Executive Officer 9 2
Edward Zhong Executive Officer 6 2
Yanni Souroutzidis Executive Officer 4 2
Edward Callaway Executive Officer 4 2
Derek Gould Executive Officer 3 2
Logos GP LLC Executive Officer 3 2
View All
EDGAR Form CIK 2011 - 2026
13F-HR [0001792126]
3 [0001792126]
4 [0001792126]
SC 13D [0001792126]
SC 13G [0001792126]
Form 13D/13G Filer Form 13D/13G Subject Filed
Logos Global Management LP Avalo Therapeutics Inc [2026-04-01]
Logos Global Management LP Tenax Therapeutics Inc [2026-03-09]
Logos Global Management LP Minerva Neurosciences Inc [2026-02-17]
Logos Global Management LP IBIO Inc [2025-12-19]
Logos Global Management LP Palatin Technologies Inc [2025-11-14]
Logos Global Management LP Erasca Inc [2025-08-14]
Logos Global Management LP Verastem Inc [2025-07-28]
Logos Global Management LP Arvinas Inc [2025-06-16]
Logos Global Management LP Prothena Corp Public Ltd Co [2025-06-04]
Logos Global Management LP Annexon Inc [2025-04-28]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund
LEI5493000DTXD20QIYQ102
Form 3/4/5 Subject 2011 - 2026
Verve Therapeutics Inc
Logos Global Management LP
Tokai Pharmaceuticals Inc
Dyne Therapeutics Inc
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Verve Therapeutics Inc VERV
Common Stock
2021-06-21 Buy 370,000 $19.00 7,030,000
Verve Therapeutics Inc VERV
Series B Preferred Stock · derivative
2021-06-21 Conversion 4,104,416
Verve Therapeutics Inc VERV
Common Stock
2021-06-21 Conversion 443,265
Tokai Pharmaceuticals Inc NVUS
Common Stock
2020-10-30 Sell 12,942 $26.64 344,775
Tokai Pharmaceuticals Inc NVUS
Common Stock
2020-10-30 Buy 12,942 $25.88 334,939
Tokai Pharmaceuticals Inc NVUS
Common Stock
2020-10-30 Sell 27 $27.02 730
Tokai Pharmaceuticals Inc NVUS
Common Stock
2020-10-30 Buy 15,000 $26.17 392,550
Tokai Pharmaceuticals Inc NVUS
Common Stock
2020-10-30 Buy 5,000 $24.03 120,150
Tokai Pharmaceuticals Inc NVUS
Common Stock
2020-10-30 Buy 31,000 $24.53 760,430
Tokai Pharmaceuticals Inc NVUS
Common Stock
2020-10-30 Buy 4,000 $25.97 103,880
Tokai Pharmaceuticals Inc NVUS
Common Stock
2020-10-30 Buy 15,000 $26.48 397,200
Tokai Pharmaceuticals Inc NVUS
Common Stock
2020-10-30 Buy 9,098 $25.55 232,454
Dyne Therapeutics Inc DYN
Series B Preferred Stock · derivative
2020-09-21 Conversion 2,668,089 $0.00
Dyne Therapeutics Inc DYN
Common Stock
2020-09-21 Conversion 804,392
Dyne Therapeutics Inc DYN
Common Stock
2020-09-21 Buy 700,000 $19.00 13,300,000
Comparable Firms State AUM
Jana Partners Management LP
NY 2,286.4 M
Clocktower Group LP
CA 2,283.0 M
Asset Value Investors Limited
2,280.8 M
M Square Investimentos LTDA
2,251.5 M
Browning West LP
CA 2,243.7 M
Troluce Capital Advisors LLC
PR 2,242.4 M
Entropy Technologies LP
NY 2,238.1 M
Passaic Partners LLC
NJ 2,237.5 M
Absolute Investment Advisers LLC
FL 2,233.9 M
APS Asset Management PTE Ltd
2,225.9 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com